|
|
Volumn 23, Issue 57, 2004, Pages 9155-9161
|
|
Malignant mesothelioma as both a challenge and an opportunity
|
|
Author keywords
IMIG; Meeting; Mesothelioma
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
ASBESTOS;
B7 ANTIGEN;
BIOLOGICAL MARKER;
BORTEZOMIB;
CANCER TESTIS ANTIGEN;
CD86 ANTIGEN;
CHRYSOTILE;
CISPLATIN;
GEMCITABINE;
GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;
IMATINIB;
IMMUNOMODULATING AGENT;
INTERLEUKIN 12;
INTERLEUKIN 2;
INTERLEUKIN 4;
MITOGEN ACTIVATED PROTEIN KINASE;
PEMETREXED;
PHA 665752;
RALTITREXED;
TRANSFORMING GROWTH FACTOR BETA;
TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;
UNCLASSIFIED DRUG;
APOPTOSIS;
CANCER EPIDEMIOLOGY;
CANCER IMMUNOTHERAPY;
CANCER SURVIVAL;
CARCINOGENICITY;
CONFERENCE PAPER;
GENETIC MODEL;
GENOMICS;
HUMAN;
IMAGING;
IMMUNOHISTOCHEMISTRY;
INTENSITY MODULATED RADIATION THERAPY;
ITALY;
LUNG RESECTION;
MALIGNANT MESOTHELIOMA;
PRIORITY JOURNAL;
PROTEOMICS;
SIMIAN VIRUS 40;
SYMPOSIUM;
TUMOR SUPPRESSOR GENE;
CARCINOGENS;
GENETIC PREDISPOSITION TO DISEASE;
GENOMICS;
HUMANS;
IMMUNOHISTOCHEMISTRY;
MESOTHELIOMA;
BRESCIA;
SIMIAE;
SIMIAN VIRUS;
SIMIAN VIRUS 40;
|
|
EID: 11244258262
PISSN: 09509232
EISSN: None
Source Type: Journal
DOI: 10.1038/sj.onc.1208180 Document Type: Conference Paper |
|
Times cited : (4)
|
|
References (0)
|
